{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T04:21:51Z","timestamp":1745986911496,"version":"3.40.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"DOI":"10.7759\/cureus.83200","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T19:24:06Z","timestamp":1745954646000},"source":"Crossref","is-referenced-by-count":0,"title":["Screening for Dyslipidemia Among Patients Admitted With Acute Coronary Syndrome at the Jakaya Kikwete Cardiac Institute, Tanzania: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Naki","family":"Kiroga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"Roth GA","year":"2017","unstructured":"Roth GA, Johnson C, Abajobir A, et al.. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017, 70:1-25. 10.1016\/j.jacc.2017.04.052","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.114.302782","article-title":"Global perspective on acute coronary syndrome: a burden on the young and poor","volume":"114","author":"Vedanthan R","year":"2014","unstructured":"Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. Circ Res. 2014, 114:1959-75. 10.1161\/CIRCRESAHA.114.302782","journal-title":"Circ Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132620","article-title":"Immune and inflammatory mechanisms of atherosclerosis (*)","volume":"27","author":"Galkina E","year":"2009","unstructured":"Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol. 2009, 27:165-97. 10.1146\/annurev.immunol.021908.132620","journal-title":"Annu Rev Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1074248420947633","article-title":"Prevalence and predictors of out-of-target LDL cholesterol 1 to 3 years after myocardial infarction. a subanalysis from the EYESHOT post-MI registry","volume":"26","author":"Silverio A","year":"2021","unstructured":"Silverio A, Benvenga RM, Piscione F, et al.. Prevalence and predictors of out-of-target LDL cholesterol 1 to 3 years after myocardial infarction. a subanalysis from the EYESHOT post-MI registry. J Cardiovasc Pharmacol Ther. 2021, 26:149-57. 10.1177\/1074248420947633","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref5","article-title":"Prevalence and pattern of dyslipidemia in acute coronary syndrome patients admitted to medical intensive care unit in Zagazig University Hospital, Egypt","volume":"20","author":"Abdelaziz A","year":"2014","unstructured":"Abdelaziz A, Fawzy M. Prevalence and pattern of dyslipidemia in acute coronary syndrome patients admitted to medical intensive care unit in Zagazig University Hospital, Egypt. Zagazig Univ Med J. 2014, 20:1-10.","journal-title":"Zagazig Univ Med J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908610","article-title":"Population trends in the incidence and outcomes of acute myocardial infarction","volume":"362","author":"Yeh RW","year":"2010","unstructured":"Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010, 362:2155-65. 10.1056\/NEJMoa0908610","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237249","article-title":"Comparison of current international guidelines for the management of dyslipidemia","volume":"11","author":"Aygun S","year":"2022","unstructured":"Aygun S, Tokgozoglu L. Comparison of current international guidelines for the management of dyslipidemia. J Clin Med. 2022, 11:7249. 10.3390\/jcm11237249","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.16-6-s43","article-title":"Acute coronary syndromes","volume":"16","author":"Kotecha T","year":"2016","unstructured":"Kotecha T, Rakhit RD. Acute coronary syndromes. Clin Med (Lond). 2016, 16:s43-8. 10.7861\/clinmedicine.16-6-s43","journal-title":"Clin Med (Lond)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.018897","article-title":"Lipid management in patients presenting with acute coronary syndromes: a review","volume":"9","author":"Claessen BE","year":"2020","unstructured":"Claessen BE, Guedeney P, Gibson CM, Angiolillo DJ, Cao D, Lepor N, Mehran R. Lipid management in patients presenting with acute coronary syndromes: a review. J Am Heart Assoc. 2020, 9:e018897. 10.1161\/JAHA.120.018897","journal-title":"J Am Heart Assoc"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach F","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al.. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020, 41:111-88. 10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d8059","article-title":"Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study","volume":"344","author":"Smolina K","year":"2012","unstructured":"Smolina K, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: linked national database study. BMJ. 2012, 344:d8059. 10.1136\/bmj.d8059","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.799981","article-title":"Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction","volume":"119","author":"Chan MY","year":"2009","unstructured":"Chan MY, Sun JL, Newby LK, et al.. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction. Circulation. 2009, 119:3110-7. 10.1161\/CIRCULATIONAHA.108.799981","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32378","article-title":"Patterns of dyslipidemia among acute coronary syndrome (ACS) patients at a tertiary care hospital in Lahore, Pakistan","volume":"14","author":"Muneeb M","year":"2022","unstructured":"Muneeb M, Khan AH, Khan Niazi A, Khan MU, Chatha ZJ, Kazmi T, Shahid N. Patterns of dyslipidemia among acute coronary syndrome (ACS) patients at a tertiary care hospital in Lahore, Pakistan. Cureus. 2022, 14:e32378. 10.7759\/cureus.32378","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-020-00631-z","article-title":"NDSP 05: prevalence and pattern of dyslipidemia in urban and rural areas of Pakistan; a sub analysis from second National Diabetes Survey of Pakistan (NDSP) 2016-2017","volume":"19","author":"Basit A","year":"2020","unstructured":"Basit A, Sabir S, Riaz M, Fawwad A. NDSP 05: prevalence and pattern of dyslipidemia in urban and rural areas of Pakistan; a sub analysis from second National Diabetes Survey of Pakistan (NDSP) 2016-2017. J Diabetes Metab Disord. 2020, 19:1215-25. 10.1007\/s40200-020-00631-z","journal-title":"J Diabetes Metab Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3473042","article-title":"Prevalence of dyslipidemia in undiagnosed Palestinian men: a cross-sectional study","volume":"2019","author":"Ali I","year":"2019","unstructured":"Ali I, Kharma A, Samara M, Odeh S, Jaradat N, Zaid AN, Ahmad MA. Prevalence of dyslipidemia in undiagnosed Palestinian men: a cross-sectional study. J Lipids. 2019, 2019:3473042. 10.1155\/2019\/3473042","journal-title":"J Lipids"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096808","article-title":"Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study","volume":"9","author":"Joshi SR","year":"2014","unstructured":"Joshi SR, Anjana RM, Deepa M, et al.. Prevalence of dyslipidemia in urban and rural India: the ICMR-INDIAB study. PLoS One. 2014, 9:e96808. 10.1371\/journal.pone.0096808","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41402","article-title":"A retrospective study on the adoption of lipid management guidelines in post-myocardial infarction patients in a tertiary care centre","volume":"15","author":"Wambua PM","year":"2023","unstructured":"Wambua PM, Khan Z, Kariuki CM, Ogola EN. A retrospective study on the adoption of lipid management guidelines in post-myocardial infarction patients in a tertiary care centre. Cureus. 2023, 15:e41402. 10.7759\/cureus.41402","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062444","article-title":"Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice","volume":"12","author":"Bosco G","year":"2023","unstructured":"Bosco G, Di Giacomo Barbagallo F, Spampinato S, et al.. Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice. J Clin Med. 2023, 12:2444. 10.3390\/jcm12062444","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim BK","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, et al.. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022, 400:380-90. 10.1016\/S0140-6736(22)00916-3","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy SM","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019, 73:3168-209. 10.1016\/j.jacc.2018.11.002","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2022-321414","article-title":"National Institute for Health and Care Excellence guidelines for lipid management","volume":"109","author":"Cegla J","year":"2023","unstructured":"Cegla J. National Institute for Health and Care Excellence guidelines for lipid management. Heart. 2023, 109:661-7. 10.1136\/heartjnl-2022-321414","journal-title":"Heart"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049662","article-title":"Global prevalence of dyslipidaemia in adult populations: a systematic review protocol","volume":"11","author":"Mohamed-Yassin MS","year":"2021","unstructured":"Mohamed-Yassin MS, Baharudin N, Abdul-Razak S, Ramli AS, Lai NM. Global prevalence of dyslipidaemia in adult populations: a systematic review protocol. BMJ Open. 2021, 11:e049662. 10.1136\/bmjopen-2021-049662","journal-title":"BMJ Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.athplu.2024.10.002","article-title":"A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: protocol for the EAS Lipid Registry of Africa (LIPRA)","volume":"58","author":"Reda A","year":"2024","unstructured":"Reda A, Lyons AR, Zambon A, et al.. A collaborative effort across Africa to investigate risk factors and outcomes of premature acute coronary syndrome: protocol for the EAS Lipid Registry of Africa (LIPRA). Atheroscler Plus. 2024, 58:46-50. 10.1016\/j.athplu.2024.10.002","journal-title":"Atheroscler Plus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30275-4","article-title":"Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis","volume":"6","author":"Noubiap JJ","year":"2019","unstructured":"Noubiap JJ, Bigna JJ, Nansseu JR, et al.. Prevalence of dyslipidaemia among adults in Africa: a systematic review and meta-analysis. Lancet Glob Health. 2019, 6:998-1007. 10.1016\/S2214-109X(18)30275-4","journal-title":"Lancet Glob Health"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v16.i5.282","article-title":"Assessment of post-myocardial infarction lipid levels and management: results from a tertiary care hospital of Pakistan","volume":"16","author":"Rauf R","year":"2024","unstructured":"Rauf R, Soomro MI, Khan MN, Kumar M, Soomro NA, Kazmi KA. Assessment of post-myocardial infarction lipid levels and management: results from a tertiary care hospital of Pakistan. World J Cardiol. 2024, 16:282-92. 10.4330\/wjc.v16.i5.282","journal-title":"World J Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global burden of cardiovascular diseases and risks, 1990-2022","volume":"82","author":"Mensah GA","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJ, Roth GA. Global burden of cardiovascular diseases and risks, 1990-2022. J Am Coll Cardiol. 2023, 82:2350-473. 10.1016\/j.jacc.2023.11.007","journal-title":"J Am Coll Cardiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20187239","article-title":"Plasma lipid abnormalities in Pakistani population: trends, associated factors, and clinical implications","volume":"51","author":"Zaid M","year":"2018","unstructured":"Zaid M, Hasnain S. Plasma lipid abnormalities in Pakistani population: trends, associated factors, and clinical implications. Braz J Med Biol Res. 2018, 51:e7239. 10.1590\/1414-431X20187239","journal-title":"Braz J Med Biol Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.31729\/jnma.4765","article-title":"Prevalence of dyslipidemia in patients with acute coronary syndrome admitted at tertiary care hospital in Nepal: a descriptive cross-sectional study","volume":"58","author":"Dhungana SP","year":"2020","unstructured":"Dhungana SP, Mahato AK, Ghimire R, Shreewastav RK. Prevalence of dyslipidemia in patients with acute coronary syndrome admitted at tertiary care hospital in Nepal: a descriptive cross-sectional study. JNMA J Nepal Med Assoc. 2020, 58:204-8. 10.31729\/jnma.4765","journal-title":"JNMA J Nepal Med Assoc"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.09.008","article-title":"Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States","volume":"10","author":"Unni SK","year":"2016","unstructured":"Unni SK, Quek RG, Biskupiak J, Lee VC, Ye X, Gandra SR. Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. J Clin Lipidol. 2016, 10:63-71.e1-3. 10.1016\/j.jacl.2015.09.008","journal-title":"J Clin Lipidol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6797.276","article-title":"Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations","volume":"303","author":"Chen Z","year":"1991","unstructured":"Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991, 303:276-82. 10.1136\/bmj.303.6797.276","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs JR","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al.. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998, 279:1615-22. 10.1001\/jama.279.20.1615","journal-title":"JAMA"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent C","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al.. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010, 376:1670-81. 10.1016\/S0140-6736(10)61350-5","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"41","author":"Bor\u00e9n J","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020, 41:2313-30. 10.1093\/eurheartj\/ehz962","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon CP","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al.. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015, 372:2387-97. 10.1056\/NEJMoa1410489","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine MS","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al.. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017, 376:1713-22. 10.1056\/NEJMoa1615664","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne RA","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al.. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023, 44:3720-826. 10.1093\/eurheartj\/ehad191","journal-title":"Eur Heart J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.057","article-title":"Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol\/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women","volume":"55","author":"Arsenault BJ","year":"2009","unstructured":"Arsenault BJ, Rana JS, Stroes ES, et al.. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol\/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol. 2009, 55:35-41. 10.1016\/j.jacc.2009.07.057","journal-title":"J Am Coll Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-013-0330-5","article-title":"Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol","volume":"29","author":"Ogita M","year":"2014","unstructured":"Ogita M, Miyauchi K, Miyazaki T, et al.. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels. 2014, 29:35-41. 10.1007\/s00380-013-0330-5","journal-title":"Heart Vessels"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcaa016","article-title":"Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC\/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17","volume":"7","author":"Allahyari A","year":"2021","unstructured":"Allahyari A, Jernberg T, Lautsch D, et al.. Low-density lipoprotein-cholesterol target attainment according to the 2011 and 2016 ESC\/EAS dyslipidaemia guidelines in patients with a recent myocardial infarction: nationwide cohort study, 2013-17. Eur Heart J Qual Care Clin Outcomes. 2021, 7:59-67. 10.1093\/ehjqcco\/qcaa016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks FM","year":"1996","unstructured":"Sacks FM, Pfeffer MA, Moye LA, et al.. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996, 335:1001-9. 10.1056\/NEJM199610033351401","journal-title":"N Engl J Med"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos JA","year":"2004","unstructured":"de Lemos JA, Blazing MA, Wiviott SD, et al.. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004, 292:1307-16. 10.1001\/jama.292.11.1307","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon CP","year":"2006","unstructured":"Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006, 48:438-45. 10.1016\/j.jacc.2006.04.070","journal-title":"J Am Coll Cardiol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon CP","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al.. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350:1495-504. 10.1056\/NEJMoa040583","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt SM","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S, et al.. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014, 64:485-94. 10.1016\/j.jacc.2014.02.615","journal-title":"J Am Coll Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak RC","year":"2002","unstructured":"Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002, 40:567-72. 10.1016\/s0735-1097(02)02030-2","journal-title":"J Am Coll Cardiol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.23.2821","article-title":"Pharmacogenetic study of statin therapy and cholesterol reduction","volume":"291","author":"Chasman DI","year":"2004","unstructured":"Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004, 291:2821-7. 10.1001\/jama.291.23.2821","journal-title":"JAMA"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.108.818062","article-title":"Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort","volume":"2","author":"Thompson JF","year":"2009","unstructured":"Thompson JF, Hyde CL, Wood LS, et al.. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ Cardiovasc Genet. 2009, 2:173-81. 10.1161\/CIRCGENETICS.108.818062","journal-title":"Circ Cardiovasc Genet"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman DI","year":"2012","unstructured":"Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012, 5:257-64. 10.1161\/CIRCGENETICS.111.961144","journal-title":"Circ Cardiovasc Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/353264-screening-for-dyslipidemia-among-patients-admitted-with-acute-coronary-syndrome-at-the-jakaya-kikwete-cardiac-institute-tanzania-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T19:24:07Z","timestamp":1745954647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/353264-screening-for-dyslipidemia-among-patients-admitted-with-acute-coronary-syndrome-at-the-jakaya-kikwete-cardiac-institute-tanzania-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.83200","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}